College Hospital Costa Mesa discovers more patient info exposed in 2024 data breach
Those impacted were notified that a 'threat actor' had accessed certain files within the hospital sometime between Aug. 14 and Sept. 17 and may have obtained personal patient data, including names, diagnoses, dates of birth and Social Security numbers.
The hospital reportedly contracted with Chicago-based data breach law firm Strauss Borrelli PLLC to investigate the incident by reviewing the data to determine what information had been exposed in the breach and which individuals were affected.
Information regarding patients' driver's license numbers and dates of appointments, along with other data potentially indicating a person had received services at the facility were part of the breach, according to a release issued Tuesday by Strauss Borrelli.
College Hospital Costa Mesa officials posted a notice of the incident on its website and, on March 10, began sending notification letters to impacted patients, the release indicated.
'We remain committed to protecting the confidentiality and security of patient information, and apologize for the concern this may cause,' the notice read. 'We are offering complimentary identity monitoring services to patients whose Social Security numbers were involved.'
Hospital representatives advised patients to carefully review statements and bills and contact their healthcare provider or insurer if they saw a charge for a service they did not receive.
In addition to implementing additional safeguards and technical security measures, College Hospital has established a toll-free call center to help answer questions about the incident, which can be reached by calling (888) 458-9763, from 6 a.m. to 6 p.m., excluding major U.S. holidays.
Those who may have received a breach notification letter and would like more information about their rights and legal remedies are asked to contact (872) 263-1100 or sam@strausborrelli.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
State Department Halts Medical Visas For Palestinians
Eight Palestinian children from Gaza named, Rahaf, Ibrahim, Jana, Mustafa, Nasser, Mohammed, Kenan, and Ahmed, arrive at O'Hare International Airport, sponsored by Palestine Children's Relief Fund (PCRF), for medical treatment in Chicago, Illinois, USA on December 2, 2024. Credit - Jacek Boczarski—Anadolu via Getty Images The State Department said it would stop issuing visas to Palestinians from Gaza, including to those coming to the United States for humanitarian and medical treatment, following a campaign by far-right political activist Laura Loomer. 'All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review of the process and procedures used to issue a small number of temporary medical-humanitarian visas in recent days,' the U.S. State Department said in a statement on Saturday. The decision will impact several programs that have evacuated dozens of critically injured children from Gaza over the last 21 months, including amputees and severe burn victims. The announcement came just hours after a series of social media posts from Loomer criticizing the medical evacuations of Palestinian children to the U.S. In one post, she shared a video of a child amputee arriving in a wheelchair at Seattle airport for medical treatment, adding: 'The Trump administration needs to shut this abomination down ASAP.' Loomer, who once described herself as a 'proud Islamaphobe' and said 9/11 was an 'inside job,' made false claims in her posts and said she had sent her 'evidence' to Secretary of State Marco Rubio. Hours later, the pause was announced. Read more: I Can No Longer Feed Kids in Gaza Rubio told "Face the Nation" on CBS on Sunday that the action came after "outreach from multiple congressional offices asking questions about it." But Loomer quickly took credit for the pause, posting: 'It's amazing how fast we can get results from the Trump administration.' The Palestinian Children Relief Fund (PCRF), a charity that organizes medical evacuations of children to the U.S., said the move will prevent them from providing 'lifesaving medical treatment' for 'critically ill children' from Gaza. 'Medical evacuations are a lifeline for the children of Gaza who would otherwise face unimaginable suffering or death due to the collapse of medical infrastructure in Gaza,' the PCRF said in a statement. According to the World Health Organization (WHO), Gaza's health system has been in collapse, and there has been a 'relentless and systematic decimation of hospitals in Gaza.' The United Nations children's charity, UNICEF, said in July that more than 17,000 children have been killed and 33,000 injured in Gaza in the last 21 months. HEAL Palestine, another charity that organizes evacuations and which was specifically targeted by Loomer in her posts, said this month it has evacuated 63 injured children and 148 total evacuees to the U.S. to receive treatment. Earlier this month, it carried out the largest known evacuation of wounded children from Gaza to the U.S., which included 11 children and their families, most of them for treatment of amputations. HEAL Palestine made it clear on social media that the visas it uses to bring people to the U.S. for treatment were not for resettlement, but for lifesaving care, contrary to Loomer's claims. 'After their treatment is complete, the children and any accompanying family members return to the Middle East. This is a medical treatment program, not a refugee resettlement program,' HEAL Palestine said Saturday. The charity added that U.S. tax dollars do not fund the treatment provided to these children. Loomer, a conspiracy theorist with a history of using hate speech to gain attention, has acquired an outsized influence over the White House in President Donald Trump's second term. She has successfully lobbied to remove people from top government roles whom she considers disloyal to the president, including six from the National Security Council, a senior Customs and Border Protection official, and a Food and Drug Administration vaccine official. TIME has contacted the State Department for comment. Contact us at letters@ Solve the daily Crossword
Epoch Times
11 hours ago
- Epoch Times
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.
Los Angeles Times
14 hours ago
- Los Angeles Times
Unlocking Cellular Health With Science and Trust
In the longevity and wellness space, Niagen Bioscience is charting a course defined by both scientific rigor and an unwavering commitment to responsible innovation Niagen Bioscience (NASDAQ: NAGE, formerly Chromadex) is a Los Angeles-based company dedicated to advancing the supplements industry using science-backed research into their component ingredients. At the helm is CEO Robert Fried, who says the company's mission is to pioneer NAD+ research and develop transformative NAD-boosting healthy-aging solutions with Niagen, their patented form of nicotinamide riboside (NR). Niagen is the cornerstone of the company's clinically proven product portfolio, Tru Niagen and Niagen IV and injections. During this year's Cannes Lions, Fried sat down with LA Times Studios to discuss how the company is pioneering the NAD+ space and the science and quality backed benefits of its Niagen products. 'NAD+, or nicotinamide adenine dinucleotide, is a co-enzyme found in all living cells – plant and animal – and is involved in all important metabolic processes within the cell, but especially energy metabolism and DNA repair, which are key to supporting mitochondrial health and overall optimal health.' explained Fried. Mitochondria, the 'battery pack of the cell,' combines nutrients from the food you eat and oxygen with NAD+ to produce energy. NAD+ also plays a crucial role in DNA recovery and cellular repair. 'All of these processes that exist within the cell where the cell repairs damage are NAD+ dependent,' Fried emphasized, illustrating how higher NAD+ levels facilitate rapid healing, contrasting youthful recovery with a slower healing process that occurs as we age. This is because NAD+ starts to decline naturally in our 30s, with research showing a dramatic drop of up to 65% by the time we reach age 70. Exposure to stressors like sedentary lifestyle, excess sun exposure, poor diet and environmental factors also impact NAD+ levels. Research shows that NAD+ decline is associated with a decline in overall health and vitality, contributing to the development of conditions and disease. Fried is quick to address a significant industry misconception: 'NAD+ itself is not bioavailable. If you consume NAD+ orally or with an IV, it will not elevate NAD+ levels inside your cells.' He clarified that the NAD+ molecule is too large to penetrate cells, causing NAD+ supplements and IV to be ineffective. Intact NAD+ may even have the potential to cause acute immune inflammatory response, which may be responsible for the uncomfortable side effects associated with NAD+ IV and injections. The solution, according to Fried, is 'to consume an NAD+ precursor molecule that easily gets into the cell and then converts into NAD+, and the best molecule for this is called nicotinamide riboside or NR.' Niagen is patented NR and precisely what Tru Niagen and pharmaceutical-grade Niagen IV and injections offer. With a legacy spanning over 25 years, the company's recent rebranding from ChromaDex to Niagen Bioscience reflects its sharpened focus. 'We're no longer only a reference standards company but an NAD+ company dedicated to addressing one of life's most complex challenges - aging,' said Fried. Niagen Bioscience differentiates itself by operating as an 'R&D lab that specializes in NAD+,' not simply a supplement distributor, he said. Its distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and an external research program helping independent investigators and institutions worldwide uncover the potential of NAD+. 'There is no other company in the supplement space that comes close this level of R&D investment and scientific research,' Fried asserted. The company boasts 38 peer-reviewed, published human clinical studies on oral food-grade Niagen, of which about 95% are completely independent, with another 40 studies currently underway. This level of scientific rigor, he contends, is typically found only in biotech or pharmaceutical companies. Products are tested at the manufacturing facility and then retested upon delivery. Fried notes their marketing: 'We are real. We are genuine. We let the science do the talking.' This approach, he believes, is key to building genuine trust. Niagen Bioscience is exploring Niagen's broader therapeutic potential for its patented NR. Fried reveals extensive clinical studies on the benefits of its patented food-grade NR for specific age-related and orphan diseases (rare conditions characterized by rapid aging). Some of these studies have reached Phase II and III clinical trials. A 52 week, 400-participant, Phase III double-blinded, controlled study on Parkinson's disease recently concluded, conducted with a world-renowned independent researcher. 'That is a level of scientific research ... that you don't see from supplement companies,' Fried emphasized. Niagen Bioscience is also innovating beyond oral supplements. They've developed a pharmaceutical-grade version of nicotinamide riboside, now available as Niagen IV. exclusively at clinics across the U.S. Fried highlighted its advantages: 'If you do an injection or an IV, you're getting the benefits of Niagen directly to the bloodstream.' This results in faster absorption and avoids side effects often associated with direct NAD+ infusions. Fried candidly addresses his concern about a lack of public trust in the dietary supplement industry, citing prevalent unsubstantiated claims, low-quality products, and marketing hype. 'It's my belief that if people genuinely trusted the companies that the industry at large would be so significant because we'd actually have preventative health value,' he states. To combat this, Niagen Bioscience has proposed a 'Trust Alliance' – a coalition of industry players, government and non-profits to test products and ensure claims are met. For Fried, the most meaningful aspect of his journey is receiving letters from individuals who experienced health benefits after taking Tru Niagen. Looking ahead, Niagen Bioscience aims to solidify its position as the 'gold standard in the NAD+ space,' continuing its scientific leadership. 'Our mission is to help every living being around the world age better. We think what could happen in the next five years is very exciting and special,' Fried concluded.
